Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Covid-19 | D000086382 | — | U07.1 | — | 1 | 2 | — | — | 2 |
Chronic renal insufficiency | D051436 | — | N18 | — | — | 2 | — | — | 2 |
Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | — | — | 1 |
Venous insufficiency | D014689 | — | — | — | — | 1 | — | — | 1 |
Thrombosis | D013927 | — | — | — | — | 1 | — | — | 1 |
Post-acute covid-19 syndrome | D000094024 | — | — | — | — | 1 | — | — | 1 |
Drug common name | Sulodexide |
INN | sulodexide |
Description | Sulodexide, traded as Aterina, is a highly purified mixture of glycosaminoglycans composed of heparan sulfate (80%) and dermatan sulfate (20%).
|
Classification | Unknown |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL2108086 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB06271 |
UNII ID | 75HGV0062C (ChemIDplus, GSRS) |